Correction: Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection (PLoS ONE (2013) 8, 11 (e81330) DOI: 10.1371/journal.pone.0081330);Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Song, Yang ^a   Garg, Shashank ^b   Girotra, Mohit ^b   Maddox, Cynthia ^a   Von Rosenvinge, Erik C ^a   Dutta, Anand ^b   Dutta, Sudhir ^a,b   Fricke, W Florian ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b SINAI HOSPITAL OF BALTIMORE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; IMMUNOGLOBULIN; RNA 16S; VANCOMYCIN;

16S RRNA GENE; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; ASYMPTOMATIC INFECTION; BIOLOGICAL THERAPY; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DIARRHEA; ENTEROBACTERIACEAE; ENTEROCOCCACEAE; FECAL MICROBIOTA TRANSPLANTATION; FECES ANALYSIS; FECES MICROFLORA; FEMALE; FIRMICUTES; HUMAN; KEYSTONE SPECIES; LACHNOSPIRACEAE; MALE; MICROBIAL DIVERSITY; MIDDLE AGED; NONHUMAN; PROTEOBACTERIA; PYROSEQUENCING; RECURRENT CLOSTRIDIUM DIFFICILE INFECTION; RECURRENT INFECTION; RELAPSE; RUMINOCOCCACEAE; STREPTOCOCCACEAE; URINARY TRACT INFECTION;

AGED; ANTI-BACTERIAL AGENTS; BIODIVERSITY; BIOLOGICAL THERAPY; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METAGENOME; MICROBIOTA; MIDDLE AGED; RNA, RIBOSOMAL, 16S; TREATMENT OUTCOME;

EID: 84896708902     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104471     Document Type: Erratum

References (70)

1. Bartlett JG (2002) Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 346: 334-339.
2. Jobe BA, Grasley A, Deveney KE, Deveney CW, Sheppard BC (1995) Clostridium difficile colitis: an increasing hospital-acquired illness. Am J Surg 169: 480-483.
3. Miller BA, Chen LF, Sexton DJ, Anderson DJ (2011) Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile Infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol 32: 387-390.
4. Rivera EV, Woods S (2003) Prevalence of asymptomatic Clostridium difficile colonization in a nursing home population: a cross-sectional study. J Gend Specif Med 6: 27-30. (Pubitemid 36790210)
5. Jangi S, Lamont JT (2010) Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life. J Pediatr Gastroenterol Nutr 51: 2-7.
6. McFarland LV, Elmer GW, Surawicz CM (2002) Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 97: 1769-1775. (Pubitemid 34761404)
7. Pepin J, Routhier S, Gagnon S, Brazeau I (2006) Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 42: 758-764. (Pubitemid 43363928)
8. Surawicz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, et al. (2000) The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 31: 1012-1017. (Pubitemid 32299362)
9. Musher DM, Logan N, Mehendiratta V, Melgarejo NA, Garud S, et al. (2007) Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 59: 705-710. (Pubitemid 47073405)
10. Buggy BP, Fekety R, Silva J Jr (1987) Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. J Clin Gastroenterol 9: 155-159. (Pubitemid 17046362)
11. Berman AL (2007) Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea. J Clin Gastroenterol 41: 932-933.
12. Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN (2007) Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 44: 846-848. (Pubitemid 46365312)
13. Garey KW, Jiang ZD, Bellard A, Dupont HL (2009) Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol 43: 91-93.
14. Johnson S, Schriever C, Patel U, Patel T, Hecht DW, et al. (2009) Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe 15: 290-291.
15. Navaneethan U, Venkatesh PG, Shen B (2010) Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship. World J Gastroenterol 16: 4892-4904.
16. Forster AJ, Taljaard M, Oake N, Wilson K, Roth V, et al. (2012) The effect of hospital-acquired infection with Clostridium difficile on length of stay in hospital. CMAJ 184: 37-42.
17. Daneman N, Stukel TA, Ma X, Vermeulen M, Guttmann A (2012) Reduction in Clostridium difficile infection rates after mandatory hospital public reporting: findings from a longitudinal cohort study in Canada. PLoS Med 9: e1001268.
18. O'Keefe SJ (2010) Tube feeding, the microbiota, and Clostridium difficile infection. World J Gastroenterol 16: 139-142.
19. Pohl JF (2012) Clostridium difficile infection and proton pump inhibitors. Curr Opin Pediatr 24: 627-631.
20. Sartor RB (2008) Microbial influences in inflammatory bowel diseases. Gastroenterology 134: 577-594.
21. Kelly CP, LaMont JT (2008) Clostridium difficile-more difficult than ever. N Engl J Med 359: 1932-1940.
22. Maroo S, Lamont JT (2006) Recurrent clostridium difficile. Gastroenterology 130: 1311-1316.
23. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, et al. (2005) An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353: 2433-2441. (Pubitemid 41770164)
24. Lund-Tonnesen S, Berstad A, Schreiner A, Midtvedt T (1998) [Clostridium difficile-associated diarrhea treated with homologous feces]. Tidsskr Nor Laegeforen 118: 1027-1030.
25. Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ (2010) Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 44: 354-360.
26. Wettstein A, Borody TJ, Leis S, Chongan J, Torres M, et al. (2007) Faecal bacteriotherapy - an effective treatment for relapsing symptomatic Clostridium difficile infection. 15th Gut United European Gastroenterology Week (France) 39(Suppl 1): A303 Vienna: United European Gastroenterology Federation.
27. Brandt LJ, Aroniadis OC, Mellow M, Kanatzar A, Kelly C, et al. (2012) Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 107: 1079-1087.
28. Gough E, Shaikh H, Manges AR (2011) Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 53: 994-1002.
29. Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, et al. (2011) Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 9: 1044-1049.
30. Vrieze A, de Groot PF, Kootte RS, Knaapen M, van Nood E, et al. (2013) Fecal transplant: a safe and sustainable clinical therapy for restoring intestinal microbial balance in human disease? Best Pract Res Clin Gastroenterol 27: 127-137.
31. Anderson JL, Edney RJ, Whelan K (2012) Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 36: 503-516.
32. Musa S, Thomson S, Cowan M, Rahman T (2010) Clostridium difficile infection and inflammatory bowel disease. Scand J Gastroenterol 45: 261-272.
33. Kump PK, Grochenig HP, Lackner S, Trajanoski S, Reicht G, et al. (2013) Alteration of Intestinal Dysbiosis by Fecal Microbiota Transplantation Does not Induce Remission in Patients with Chronic Active Ulcerative Colitis. Inflamm Bowel Dis 19: 2155-2165.
34. Vrieze A, Van Nood E, Holleman F, Salojarvi J, Kootte RS, et al. (2012) Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143: 913-916 e917
35. Borody TJ, Paramsothy S, Agrawal G (2013) Fecal microbiota transplantation: indications, methods, evidence, and future directions. Curr Gastroenterol Rep 15: 337.
36. Borody TJ, Khoruts A (2012) Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol 9: 88-96.
37. U.S. Department of Health and Human Services FaDA, Center for Biologics Evaluation and Research (2013) Guidance for Industry: Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies. 1-4.
38. Aas J, Gessert CE, Bakken JS (2003) Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 36: 580-585. (Pubitemid 36259562)
39. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, et al. (2011) Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A 108 Suppl 1: 4680-4687.
40. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, et al. (2010) QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7: 335-336.
41. Angiuoli SV, Matalka M, Gussman A, Galens K, Vangala M, et al. (2011) CloVR: a virtual machine for automated and portable sequence analysis from the desktop using cloud computing. BMC Bioinformatics 12: 356.
42. James White WFF, Cesar Arze, Malcolm Matalka, The CloVR Team, Owen White, et al. (2011) CloVR-16S: Phylogenetic microbial community composition analysis based on 16S ribosomal RNA amplicon sequencing - standard operating procedure, version1.0. Nature Precedings.
43. Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R (2011) UCHIME improves sensitivity and speed of chimera detection. Bioinformatics 27: 2194-2200.
44. Wang Q, Garrity GM, Tiedje JM, Cole JR (2007) Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol 73: 5261-5267. (Pubitemid 47326658)
45. Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, et al. (2009) Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol 75: 7537-7541.
46. White JR, Nagarajan N, Pop M (2009) Statistical methods for detecting differentially abundant features in clinical metagenomic samples. PLoS Comput Biol 5: e1000352.
47. Price MN, Dehal PS, Arkin AP (2010) FastTree 2 - approximately maximum-likelihood trees for large alignments. PLoS One 5: e9490.
48. Dutta SK, Garg S, Dutta A, von Rosenvinge EC, Maddox C, et al. (2013) Jejunal and Colonic Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection with genomic analysis. Gastroenterology ID: AJG-13- 1181submitted.
49. Skraban J, Dzeroski S, Zenko B, Mongus D, Gangl S, et al. (2013) Gut microbiota patterns associated with colonization of different Clostridium difficile ribotypes. PLoS One 8: e58005.
50. Shahinas D, Silverman M, Sittler T, Chiu C, Kim P, et al. (2012) Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16S rRNA gene deep sequencing. MBio 3.
51. Antharam VC, Li E, Ishmael A, Sharma A, Mai V, et al. (2013) Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J Clin Microbiol.
52. Lawley TD, Clare S, Walker AW, Stares MD, Connor TR, et al. (2012) Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog 8: e1002995.
53. Lawley TD, Clare S, Walker AW, Goulding D, Stabler RA, et al. (2009) Antibiotic treatment of clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts. Infect Immun 77: 3661-3669.
54. Petrof EO, Gloor GB, Vanner SJ, Weese SJ, Carter D, et al. (2012) Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome 1.
55. Lawley B, Tannock GW (2012) Nucleic acid-based methods to assess the composition and function of the bowel microbiota. Gastroenterol Clin North Am 41: 855-868.
56. Ludwig W, Schleifer K-H, Whitman WB (2009) Revised road map to the phylum Firmicutes. In: Bergey's Manual of Systematic Bacteriology, ed., vol. 3 (The Firmicutes) (P. De Vos, G. Garrity, D. Jones, N.R. Krieg, W. Ludwig, F.A. Rainey, K.-H. Schleifer, and W.B. Whitman, eds.). Springer-Verlag, New York: 1-13.
57. Derrien M, Vaughan EE, Plugge CM, de Vos WM (2004) Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol 54: 1469-1476. (Pubitemid 39359958)
58. Belzer C, de Vos WM (2012) Microbes inside - from diversity to function: the case of Akkermansia. ISME J 6: 1449-1458.
59. Power ME, Tilman D, Estes JA, Menge BA, Bond WJ, et al. (1996) Challenges in the quest for keystones. Bioscience 46: 609-620.
60. Ebenman B, Jonsson T (2005) Using community viability analysis to identify fragile systems and keystone species. Trends Ecol Evol 20: 568-575. (Pubitemid 41323714)
61. Hajishengallis G, Liang S, Payne MA, Hashim A, Jotwani R, et al. (2011) Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal microbiota and complement. Cell Host Microbe 10: 497-506.
62. Hamilton MJ, Weingarden AR, Unno T, Khoruts A, Sadowsky MJ (2013) High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes 4: 125-135.
63. Reeves AE, Koenigsknecht MJ, Bergin IL, Young VB (2012) Suppression of Clostridium difficile in the gastrointestinal tracts of germfree mice inoculated with a murine isolate from the family Lachnospiraceae. Infect Immun 80: 3786-3794.
64. Human Microbiome Project C (2012) Structure, function and diversity of the healthy human microbiome. Nature 486: 207-214.
65. Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, et al. (2009) Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461: 1282-1286.
66. Roediger WE (1982) Utilization of nutrients by isolated epithelial cells of the rat colon. Gastroenterology 83: 424-429.
67. Koruda MJ, Rolandelli RH, Bliss DZ, Hastings J, Rombeau JL, et al. (1990) Parenteral nutrition supplemented with short-chain fatty acids: effect on the small-bowel mucosa in normal rats. Am J Clin Nutr 51: 685-689.
68. Peng L, He Z, Chen W, Holzman IR, Lin J (2007) Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatr Res 61: 37-41. (Pubitemid 46352313)
69. Dethlefsen L, Relman DA (2011) Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A 108 Suppl 1: 4554-4561.
70. Gorkiewicz G, Thallinger GG, Trajanoski S, Lackner S, Stocker G, et al. (2013) Alterations in the colonic microbiota in response to osmotic diarrhea. PLoS One 8: e55817.